Saturday 17 October 2026
Export ATHE’s income statement to Excel — free account
Alterity Therapeutics Limited - Sponsored ADR
ATHE Healthcare Biotechnology
Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.62
0.10
−3.68%
Follow ATHE
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 2 | 2 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
3.78 | (4.93) | (7.37) | (19.56) | 2.15 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
4.19 | (13.35) | (16.67) | (52.26) | (3.25) | — | — | — | — | — |
Beneish M-Score |
(3.57) | (3.24) | (1.78) | (10.82) | 30.19 | — | — | — | — | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.26 | 0.86 | — | — | — | — | — |
EV/Operating CF |
1.06 | 1.11 | 0.49 | 0.31 | 1.73 | — | — | — | — | — |
EV/FCF |
1.06 | 1.10 | 0.49 | 0.31 | 1.73 | — | — | — | — | — |
Quick Ratio |
15.67 | 6.95 | 5.79 | 3.41 | 10.56 | 6.79 | 5.58 | 3.10 | 10.49 | 14.26 |
Current Ratio |
15.88 | 7.06 | 5.98 | 3.62 | 10.92 | 7.07 | 6.17 | 3.54 | 12.98 | 14.52 |
Net Debt/EBITDA |
3.31 | 1.97 | 1.17 | 0.71 | 1.89 | 1.99 | 0.91 | 0.55 | 1.67 | 1.32 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.11 | 0.15 | 0.25 | 0.01 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.78 | 0.76 | 1.13 | 0.70 | 1.13 | 0.96 | 1.45 | 0.66 | 0.94 | 0.96 |
Capex/Depreciation |
(1.30) | (2.86) | (0.24) | (0.15) | (0.14) | (1.65) | (0.07) | (0.04) | 0.00 | 0.00 |
| (27.93%) | (42.26%) | (72.60%) | (108.60%) | (82.99%) | (38.44%) | (45.24%) | (102.77%) | (43.10%) | (56.26%) | |
| (26.06%) | (38.17%) | (61.37%) | (86.50%) | (72.06%) | (33.83%) | (38.41%) | (80.92%) | (37.10%) | (52.04%) | |
ROIC |
(229.92%) | (574.31%) | (358.62%) | 0.00% | (396.76%) | (1,656.09%) | (154.05%) | (1,248.22%) | (135.49%) | (327.72%) |
Return on Tangible Assets |
(31.84%) | (51.40%) | (74.37%) | (187.91%) | (50.27%) | (36.26%) | (60.75%) | (139.64%) | (28.69%) | (54.84%) |
Average Days of Receivables |
351.17 | 345.85 | 348.40 | 160.15 | 346.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
180.67% | 201.33% | 256.60% | 7,221.62% | 272.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
135.48% | 130.48% | 85.15% | 2,464.43% | 153.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | (8.63%) | 41.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(108.07%) | (39.46%) | (1.10%) | (0.23%) | (0.17%) | — | — | — | — | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — | — | — |
Revenue per Share |
2.67 | 2.90 | 3.53 | 0.06 | 1.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(4.97) | (5.44) | (9.72) | (4.25) | (4.58) | (2.23) | (3.33) | (1.36) | (0.70) | (0.87) |
Capex per Share |
(0.02) | (0.05) | 0.00 | (0.01) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(4.99) | (5.49) | (9.73) | (4.25) | (4.58) | (2.25) | (3.33) | (1.36) | (0.70) | (0.87) |
Cash per Share |
18.54 | 13.27 | 10.03 | 4.14 | 7.43 | 6.30 | 2.62 | 1.36 | 2.01 | 1.44 |
Shareholders Equity per Share |
20.07 | 14.01 | 11.54 | 3.22 | 8.05 | 6.42 | 3.80 | 1.49 | 2.58 | 1.65 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
20.07 | 14.01 | 11.54 | 3.22 | 8.05 | 6.42 | 3.80 | 1.49 | 2.58 | 1.65 |
Free Cash Flow |
(4.44) | (4.89) | (9.99) | (6.34) | (12.96) | (9.02) | (13.49) | (8.27) | (7.42) | (15.29) |
Working Capital |
17.84 | 12.41 | 11.83 | 4.78 | 22.73 | 25.63 | 15.26 | 8.96 | 27.42 | 28.96 |
Capital Expenditures |
(0.02) | (0.05) | 0.00 | (0.01) | (0.01) | (0.06) | 0.00 | 0.00 | — | — |
Net Current Asset Value |
17.84 | 12.41 | 11.81 | 4.75 | 22.70 | 25.57 | 15.18 | 8.93 | 27.36 | 28.87 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.01 | 0.02 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.69 | 0.31 | 0.61 | 2.85 | 2.41 | 0.53 | 1.65 | 4.58 | 36.20 | 392.00 |
Cash ROIC |
(12.93%) | (20.14%) | (45.10%) | (57.79%) | (29.60%) | (17.68%) | (51.94%) | (47.70%) | (15.15%) | (28.14%) |
Accounts Receivable Turnover |
0.82 | 1.09 | 1.23 | 0.05 | 2.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
2.89 | 2.37 | 2.95 | 1.75 | 1.62 | 3.31 | 4.63 | 4.24 | 2.60 | 3.89 |
Average Payables |
0.97 | 1.13 | 1.77 | 1.67 | 1.63 | 2.78 | 3.03 | 2.70 | 2.35 | 1.52 |
Average Assets |
21.82 | 16.79 | 14.38 | 10.45 | 15.87 | 27.55 | 24.20 | 15.50 | 21.21 | 30.52 |
Average Common Equity |
20.36 | 15.16 | 12.15 | 8.32 | 13.78 | 24.25 | 20.55 | 12.20 | 18.25 | 28.23 |
Columns are period end dates